You just read:

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

News provided by

Reportlinker

12 May, 2016, 19:13 ET